Compare Inovio Pharmaceuticals Inc (INO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Tripadvisor Inc Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B). The key difference: Tripadvisor Inc Common Stock is far larger — about 9× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| INO | TRIP | |
|---|---|---|
Market Cap | $112.19M | $1.01B |
Volume | 3,201,278 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $16.72 |
52-Week Low | $0.66 | $8.04 |
Typical Hold Time | 43 Days | 57 Days |
Enterprise Value | $83.51M | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
TripAdvisor (TRIP) trades at $8.63, up 1.29% on the day but near its 52-week low of $8.27. The stock is technically bearish, with recent earnings misses and a net cash outflow of $29M in 2025. Revenue grew to $1.89B in 2025, but net margins remain thin at 0.27%. Analyst sentiment is mixed, with a consensus price target of $13.58 but a majority hold rating.
The outlook is cautious. Upside potential exists if the Viator segment recovers and TheFork sale concludes, but risks include persistent earnings volatility, competitive pressure from AI travel tools, and weak cash flow trends. The stock offers value on P/S (0.57) but requires improved execution to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
